Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    November 2022
  1. LI M, Liao K, Chen AJ, Cascone T, et al
    Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
    J Natl Cancer Inst. 2022 Nov 8. pii: 6809139. doi: 10.1093.
    PubMed     Abstract available


  2. DI FEDERICO A, De Giglio A, Gelsomino F, Sperandi F, et al
    Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis.
    J Natl Cancer Inst. 2022 Nov 2. pii: 6794208. doi: 10.1093.
    PubMed     Abstract available


    October 2022
  3. YOU S, Kim M, Hoi XP, Lee YC, et al
    Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.
    J Natl Cancer Inst. 2022;114:1380-1391.
    PubMed     Abstract available


    September 2022
  4. WARKENTIN MT, Tammemagi MC, Espin-Garcia O, Budhathoki S, et al
    Lung Cancer Absolute Risk Models for Mortality in Asian Population using China Kadoorie Biobank.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694851. doi: 10.1093.
    PubMed     Abstract available


  5. PELLINEN T, Paavolainen L, Martin-Bernabe A, Papatella Araujo R, et al
    Fibroblast subsets in non-small cell lung cancer: associations with survival, mutations, and immune features.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694853. doi: 10.1093.
    PubMed     Abstract available


    August 2022
  6. SEDANI AE, Davis OC, Clifton SC, Campbell JE, et al
    Facilitators and Barriers to Implementation of Lung Cancer Screening: A Framework Driven Systematic Review.
    J Natl Cancer Inst. 2022 Aug 22. pii: 6673083. doi: 10.1093.
    PubMed     Abstract available


  7. VOGTMANN E, Hua X, Yu G, Purandare V, et al
    The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies.
    J Natl Cancer Inst. 2022 Aug 5. pii: 6656358. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  8. BROUWER AF, Engle JM, Jeon J, Meza R, et al
    Sociodemographic survival disparities for lung cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Jul 22. pii: 6648464. doi: 10.1093.
    PubMed     Abstract available


  9. TAYLOR KL, Williams RM, Li T, Luta G, et al
    A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting.
    J Natl Cancer Inst. 2022 Jul 12. pii: 6633937. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  10. CASTILHO JL, Bian A, Jenkins CA, Shepherd BE, et al
    CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.
    J Natl Cancer Inst. 2022;114:854-862.
    PubMed     Abstract available


    May 2022
  11. GABRIEL AAG, Atkins JR, Penha RCC, Smith-Byrne K, et al
    Genetic analysis of lung cancer and the germline impact on somatic mutation burden.
    J Natl Cancer Inst. 2022 May 2. pii: 6576636. doi: 10.1093.
    PubMed     Abstract available


    April 2022

  12. Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2022 Apr 1. pii: 6561908. doi: 10.1093.
    PubMed    


    February 2022
  13. TANAKA I, Dayde D, Tai MC, Mori H, et al
    SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
    J Natl Cancer Inst. 2022;114:290-301.
    PubMed     Abstract available


    December 2021
  14. CHOI E, Luo SJ, Aredo JV, Backhus LM, et al
    The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
    J Natl Cancer Inst. 2021 Dec 10. pii: 6459177. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  15. ISLAMI F, Ward EM, Sung H, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
    J Natl Cancer Inst. 2021;113:1648-1669.
    PubMed     Abstract available


  16. GAVRIELATOU N, Shafi S, Gaule P, Rimm DL, et al
    PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.
    J Natl Cancer Inst. 2021;113:1613-1614.
    PubMed    


    August 2021
  17. HOPKINS AM, Kichenadasse G, Logan JM, Rowland A, et al
    RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 27. pii: 6358733. doi: 10.1093.
    PubMed    


  18. ZHAO W, Zhu B, Hutchinson A, Pesatori AC, et al
    Clinical Implications of Inter- and Intra-Tumor Heterogeneity of Immune Cell Markers in Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 17. pii: 6353611. doi: 10.1093.
    PubMed     Abstract available


  19. DEROUEN MC, Canchola AJ, Thompson CA, Jin A, et al
    Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females.
    J Natl Cancer Inst. 2021 Aug 4. pii: 6338453. doi: 10.1093.
    PubMed     Abstract available


    July 2021
  20. CHOI E, Sanyal N, Ding VY, Gardner RM, et al
    Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
    J Natl Cancer Inst. 2021 Jul 13. pii: 6320070. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  21. WANG X, Ricciuti B, Alessi JV, Nguyen T, et al
    Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Jun 11. pii: 6296846. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  22. VERHOEVEN DC, Chollette V, Lazzara EH, Shuffler ML, et al
    The Anatomy and Physiology of Teaming in Cancer Care Delivery: A Conceptual Framework.
    J Natl Cancer Inst. 2021;113:360-370.
    PubMed     Abstract available


    December 2020
  23. MITCHELL AP, Bach PB
    Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care.
    J Natl Cancer Inst. 2020;112:1177-1178.
    PubMed    


    July 2020
  24. TAKVORIAN SU, Balogh E, Nass S, Valentin VL, et al
    Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for Action.
    J Natl Cancer Inst. 2020;112:663-670.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: